# Variant Analysis Report #8

**Gene:** BRCA1

**Variant:** NM_007294.4:c.4963T>C

---

<think>
Okay, let's tackle this variant interpretation for BRCA1 c.4963T>C. First, I need to go through each of the ACMG/AMP 2015 criteria step by step. 

Starting with the PVS1 criterion. PVS1 is for loss-of-function variants in genes where LOF is a known disease mechanism. BRCA1 is definitely a gene where LOF variants are pathogenic, like nonsense or frameshift mutations. But this is a missense variant, Ser1655Pro. Since it's not a LOF variant, PVS1 isn't met. So, PVS1 is not applicable here.

Next, the strong criteria (PS1-PS4). PS1 requires the same amino acid change as a known pathogenic variant. I don't see any mention of this exact variant in ClinVar or HGMD. The ClinVar entry says conflicting classifications, but that doesn't confirm it's the same as a known pathogenic variant. So PS1 is not met.

PS2 is about de novo variants in a patient without a family history. The data here says De novo is N/A, so we don't have evidence of it being de novo. Therefore, PS2 isn't applicable.

PS3 involves functional studies showing a damaging effect. The functional studies are all N/A, so PS3 can't be applied.

PS4 is about increased frequency in patients compared to controls. The gnomAD data is all None, so we don't have population frequency data. Without that, PS4 can't be evaluated. So PS4 is not met.

Moving to moderate criteria (PM1-PM6). PM1 checks if the variant is in a hotspot or important domain. BRCA1 has several domains like the BRCT domains. I need to check if Ser1655 is in a critical domain. If it's in a known functional domain, PM1 might be applicable. But without specific domain information, I can't confirm. Maybe I should note that it's not in a known hotspot, so PM1 might not be met.

PM2 looks at population frequency. Since gnomAD AF is None, it's either not present or very rare. If it's absent, that supports PM2. But the exact value isn't given, so I might have to assume it's very rare. So PM2 could be considered as met with a strong support.

PM3 is about trans-acting variants in a recessive disease. This is a dominant disease (BRCA1 is autosomal dominant), so PM3 isn't applicable.

PM4 is for in-frame indels or stop-loss. This is a missense, not an in-frame indel or stop-loss, so PM4 is not met.

PM5 requires that the amino acid position has other pathogenic missense variants. If there are other pathogenic variants at this position, then PM5 applies. But without data on that, I can't confirm. So PM5 is not met.

PM6 is about de novo without parental confirmation. The data says De novo is N/A, so PM6 isn't applicable.

For supporting criteria (PP1-PP5). PP1 is co-segregation in families. The family segregation data is N/A, so PP1 isn't met.

PP2 is for missense variants in genes where missense is rare. BRCA1 is a gene where missense variants are less common, but this is a missense. However, since the variant is not in a hotspot and has no population data, maybe PP2 is not applicable. Wait, PP2 is for genes where missense variants are rare. If the gene typically has few missense variants, then a missense here might be more likely pathogenic. But without knowing the gene's typical missense frequency, it's hard to say. Maybe this is a weak point.

PP3 is about computational evidence. The CADD score is 0.998, which is very low (CADD scores above 10 are considered high). REVEL is 0.847, which is also low (REVEL >0.8 is considered pathogenic). Wait, REVEL scores are typically between 0 and 1, with higher values indicating more likely pathogenic. So 0.847 is actually a high score. Wait, but the user provided CADD as 0.998, which is very low. That's conflicting. Wait, CADD scores are usually on a scale where higher is more damaging. Wait, no, CADD scores are on a scale where higher is more damaging. Wait, the user wrote CADD: 0.9987499213600626. That's a very low score, almost 1.0. Wait, but CADD scores are typically in the range of 0 to 100, with higher being more damaging. Wait, maybe there's a misunderstanding here. Let me check. Oh, no, the CADD score is actually a Phred-scaled score, where higher values are more damaging. But the value given here is 0.998, which is very low. That would suggest it's not damaging. But REVEL is 0.847, which is a high score (since REVEL is a probability, so 0.847 is 84.7% chance of being pathogenic). Wait, that's conflicting. So if CADD is low but REVEL is high, that might be a conflicting signal. But the user might have made a mistake in the CADD value. Alternatively, maybe the CADD score is presented as a probability. Wait, no, CADD is a score where higher is more damaging. So 0.998 is extremely low. That would suggest the variant is not damaging. But REVEL is 0.847, which is high. This is confusing. Maybe the user input the CADD value incorrectly. But assuming the data is correct, then the computational evidence is conflicting. So PP3 might not be met because the evidence is conflicting.

PP4 is about the patient's phenotype being specific to the gene. If the patient has a phenotype consistent with BRCA1-related cancer, then PP4 applies. But the user hasn't provided the patient's phenotype. So without that, PP4 can't be evaluated.

PP5 is about being classified as pathogenic in a reliable source. ClinVar has conflicting classifications, so PP5 isn't met.

Now, the benign criteria. BA1 is for population frequency >5%. Since gnomAD AF is None, BA1 isn't met.

BS1 is about higher frequency than expected. Again, no data, so not applicable.

BS2 is about being observed in healthy adults. No data, so not applicable.

BS3 is about functional studies showing no effect. No functional data, so not applicable.

BS4 is about lack of segregation. No data, so not applicable.

BP criteria: BP1 is for missense in a gene where LOF is the mechanism. BRCA1 is LOF, so a missense might be less likely, but BP1 is about missense in such genes. So BP1 might be applicable as a weak point.

BP2 is about trans or cis with a pathogenic variant. No data, so not applicable.

BP3 is about in-frame indels in non-functional regions. Not applicable here.

BP4 is about computational evidence suggesting no effect. If CADD is low, that might support BP4. But REVEL is high. So conflicting evidence. So BP4 might not be met.

BP5 is about alternative molecular evidence. No data.

BP6 is about being classified as benign in a reliable source. ClinVar has conflicting, so not applicable.

BP7 is about no splice effect. SpliceAI is N/A, but the variant is a missense, so no splice effect. So BP7 is met.

Putting it all together, the only criteria met are PM2 (population absence) and BP7 (no splice effect). But PM2 is a moderate criterion, and BP7 is a supporting benign criterion. However, the computational evidence is conflicting. Since there's no strong pathogenic evidence, but PM2 is moderate, and BP7 is supporting benign, but the variant is a missense in a critical gene. 

Wait, but PM2 is a moderate pathogenic criterion. If the variant is absent in population databases, that supports pathogenicity. However, the CADD score is very low, which would support benign. But REVEL is high. This is conflicting. 

In the absence of strong pathogenic evidence and with conflicting computational data, the variant might be classified as VUS. However, since PM2 is met (population absence), that's a moderate pathogenic criterion. But without other strong criteria, it's not enough to meet the pathogenic threshold. 

So the final classification would be VUS with low confidence, as there's not enough evidence to confirm pathogenicity or benignity.
</think>

### **ACMG/AMP 2015 기준 체계적 평가**

---

#### **1. 병원성 증거**

**A. 매우 강력 (PVS1):**  
- **평가:** 미충족  
- **근거:** 변이는 missense 유형으로, LOF (nonsense, frameshift, splice site 등) 변이가 아님. BRCA1은 LOF 변이가 병인 기전인 유전자이지만, 이 변이는 PVS1 기준에 해당하지 않음.  
- **강도:** 미충족  

---

**B. 강력 (PS1-PS4):**  
- **PS1:** 미충족  
  - 근거: ClinVar에서 "Conflicting_classifications_of_pathogenicity"로 분류됨. 동일한 아미노산 변화의 확립된 병원성 변이와의 동일성 증거 없음.  
- **PS2:** 미충족  
  - 근거: De novo 정보가 제공되지 않음.  
- **PS3:** 미충족  
  - 근거: 기능 연구 데이터가 없음 (In vitro, In vivo 모두 N/A).  
- **PS4:** 미충족  
  - 근거: gnomAD AF 데이터가 제공되지 않음. 환자군 대비 유병률 증가의 유의성 평가 불가.  

---

**C. 중등도 (PM1-PM6):**  
- **PM1:** 미충족  
  - 근거: BRCA1의 중요 기능 도메인 (예: BRCT 도메인)에 위치 여부 확인 불가. 현재 정보로는 핫스팟 또는 기능적 중요 영역에 속함을 판단할 수 없음.  
- **PM2:** 충족 (PM2_Supporting)  
  - 근거: gnomAD AF (전체, popmax, 동형접합) 데이터가 "None"으로 제공됨. 이는 변이가 일반 인구에서 극히 드물거나 관찰되지 않음을 시사함. BRCA1의 병원성 변이가 일반 인구에서 흔하지 않다는 점을 고려할 때, PM2_Supporting으로 평가.  
- **PM3:** 미충족  
  - 근거: 열성 질환 (BRCA1은 우성 질환)에서 trans 병원성 변이와의 연관성 증거 없음.  
- **PM4:** 미충족  
  - 근거: 변이는 missense 유형으로, in-frame indel 또는 stop-loss가 아님.  
- **PM5:** 미충족  
  - 근거: Ser1655 위치에 다른 병원성 미스센스 변이가 존재하는지 확인 불가.  
- **PM6:** 미충족  
  - 근거: De novo 여부 확인 불가.  

---

**D. 지지 (PP1-PP5):**  
- **PP1:** 미충족  
  - 근거: 가계 분리 데이터가 제공되지 않음.  
- **PP2:** 미충족  
  - 근거: BRCA1은 missense 변이가 흔한 병인 기전이 아님. 하지만 이 변이는 missense 유형으로, PP2 기준에 부합하지 않음.  
- **PP3:** 미충족  
  - 근거: 전산 예측 데이터가 모순됨.  
    - **CADD:** 0.998 (매우 낮은 점수, 유해 효과 미지지).  
    - **REVEL:** 0.847 (높은 점수, 병원성 가능성 지지).  
    - 두 예측자가 상반된 결과를 보임.  
- **PP4:** 미충족  
  - 근거: 환자의 표현형/가족력 정보가 제공되지 않음.  
- **PP5:** 미충족  
  - 근거: ClinVar에서 "Conflicting_classifications_of_pathogenicity"로 분류됨. 신뢰할 수 있는 출처에서 병원성으로 분류된 사례 없음.  

---

#### **2. 양성 증거**

**A. 단독 (BA1):**  
- **평가:** 미충족  
- **근거:** gnomAD AF 데이터가 제공되지 않음.  

---

**B. 강력 (BS1-BS4):**  
- **BS1:** 미충족  
  - 근거: 유병률, 발현율, 유전적 이질성 고려 불가.  
- **BS2:** 미충족  
  - 근거: 건강한 성인에서 관찰 여부 확인 불가.  
- **BS3:** 미충족  
  - 근거: 기능 연구 데이터가 없음.  
- **BS4:** 미충족  
  - 근거: 환자군에서의 분리 부족 정보 없음.  

---

**C. 지지 (BP1-BP7):**  
- **BP1:** 미충족  
  - 근거: BRCA1은 LOF 변이가 병인 기전인 유전자이지만, 이 변이는 missense 유형으로 BP1 기준에 부합하지 않음.  
- **BP2:** 미충족  
  - 근거: trans/cis 병원성 변이와의 연관성 증거 없음.  
- **BP3:** 미충족  
  - 근거: 반복 영역의 in-frame indel이 아님.  
- **BP4:** 미충족  
  - 근거: 전산 예측 데이터가 모순됨.  
- **BP5:** 미충족  
  - 근거: 대체 분자적 근거가 있는 증례 정보 없음.  
- **BP6:** 미충족  
  - 근거: ClinVar에서 "Conflicting_classifications_of_pathogenicity"로 분류됨.  
- **BP7:** 충족  
  - 근거: SpliceAI 데이터가 N/A이지만, 변이는 missense 유형으로 스플라이스 영향 없음. BP7 기준 충족.  

---

#### **3. 최종 분류**

**적용된 기준 요약:**  
- **병원성:** PM2_Supporting (gnomAD에서 극히 드물거나 관찰되지 않음).  
- **양성:** BP7 (스플라이스 영향 없음).  

**분류 규칙:**  
- **병원성:** (i) 매우 강력 1개 + 강력 1개, (ii) 매우 강력 1개 + 중등도 ≥2개, (iii) 매우 강력 1개 + 중등도 1개 + 지지 1개, (iv) 강력 2개, (v) 강력 1개 + 중등도 ≥3개, (vi) 강력 1개 + 중등도 2개 + 지지 ≥2개.  
- **병원성 가능:** (i) 매우 강력 1개 + 중등도 1개, (ii) 강력 1개 + 중등도 1-2개, (iii) 강력 1개 + 지지 ≥2개, (iv) 중등도 ≥3개, (v) 중등도 2개 + 지지 ≥2개, (vi) 중등도 1개 + 지지 ≥4개.  
- **VUS:** 위 범주 기준 미충족.  

**최종 분류:** **VUS (Variants of Uncertain Significance)**  
- **신뢰도:** 낮음  
- **해석 요약:**  
  - BRCA1 c.4963T>C (p.Ser1655Pro)는 missense 유형으로, gnomAD에서 극히 드물거나 관찰되지 않음 (PM2_Supporting). 하지만 전산 예측 데이터 (CADD 0.998, REVEL 0.847)가 모순됨. 기능 연구, 가계 분리, 병원성 변이와의 동일성 등 추가 증거가 부족함.  
- **권고사항:**  
  - 추가 기능 연구 (예: in vitro 기능 분석) 또는 가계 분리 데이터 수집이 필요함.  
  - ClinVar의 "Conflicting_classifications_of_pathogenicity"를 참고하여 다른 기관의 분석 결과를 검토할 필요 있음.  

--- 

**결론:**  
현재 제공된 증거로는 이 변이를 병원성 또는 양성으로 분류할 수 없으며, **VUS**로 분류됨. 추가적인 임상 및 분자적 증거가 필요함.